Irinotecan-d10 (hydrochloride)

Modify Date: 2024-01-16 04:49:40

Irinotecan-d10 (hydrochloride) structure	Common Name	Irinotecan-d10 (hydrochloride)
	CAS Number	718612-62-5	Molecular Weight	633.201
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₃₃H₂₉D₁₀ClN₄O₆	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Irinotecan-d10 (hydrochloride)

Irinotecan-d10 ((+)-Irinotecan-d10) hydrochloride is the deuterium labeled Irinotecan. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1][2].

Name	Irinotecan-d10 (hydrochloride)
Synonym	More Synonyms

Description	Irinotecan-d10 ((+)-Irinotecan-d10) hydrochloride is the deuterium labeled Irinotecan. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase Signaling Pathways >> Autophagy >> Autophagy
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [3]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [4]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. [5]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. [6]. Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21(2):130-42.

Molecular Formula	C₃₃H₂₉D₁₀ClN₄O₆
Molecular Weight	633.201
Exact Mass	632.318604

[1,4'-Bipiperidine-2,2,3,3,4,4,5,5,6,6-d10]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, hydrochloride (1 :1)

(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl (2,2,3,3,4,4,5,5,6,6-2H10)-1,4'-bipiperidine-1'-carboxylate hydrochloride (1:1)

Irinotecan-d10 (hydrochloride)

Irinotecan-d10 (hydrochloride)

Use of Irinotecan-d10 (hydrochloride)

Names

Irinotecan-d10 (hydrochloride) Biological Activity

Chemical & Physical Properties

Synonyms